Healthcare
Sihuan Pharmaceutical Holdings Group Ltd.(SHPHF)
Live Price
Offline$0.1865
+0.00% today
1Y Change
+86.50%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- $10.01B
- Revenue Growth
- +34.2%
- EPS Growth
- +180.8%
- Dividend Yield
- 0.9%
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) is a Healthcare stock with a market cap of $10.01B and listed on OTC. The stock last traded around $0.19 and up 86.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +34.2%, EPS growth of +180.8%, a dividend yield of 0.9%. What stands out right now is revenue +34.2%, EPS +180.8%, free cash flow -479.2% with operating margin 19.0% and ROIC 2.7%. The dividend is present but secondary, with a yield around 0.9%. Valuation already assumes a fairly strong business story at P/E 58.2 and price/sales 3.9. Stock Foundry combines SHPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+34.2% vs +7.6% peer median
Operating Margin
Near sector median
+19.0% vs +19.4% peer median
P/E
Above sector median
58.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +34.2% and EPS at +180.8%, with operating margin around 19.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.9%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHPHF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHPHF Max Drawdown
-23.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHPHF and SPY.
Company Overview
Sihuan Pharmaceutical Holdings Group Ltd.
Other OTC
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.
- Leadership
- Weicheng Guo
- IPO Date
- Jan 13, 2012
- Employees
- 2.7k
- Street Address
- Convention Plaza
- Mailing
- Wan Chai
- Region
- Wan Chai, HK
- Reporting Currency
- USD
- Investor Line
- 852 3628 3911
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 58.2
- EV/EBITDA
- 13.6
- Price/Sales
- 3.9
- Price/Book
- 1.8
Growth
- Revenue
- +34.2%
- EPS
- +180.8%
- Free Cash Flow
- -479.2%
Profitability
- Gross Margin
- 68.8%
- Operating Margin
- 19.0%
- Net Margin
- 6.9%
- ROE
- 3.5%
- ROIC
- 2.7%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 1.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.